Main > > >PNEUMOLOGY.

---

Asthma. Respiratory Monitoring. Weara-
ble Technology.
(*) Company; Patent & Web-Site Avai-
lable on Request.
UpDate: 2018. 09.01.




Asthma. TREAT.: BenralizuMAb SubCutaneous Inj. 30 mg.
(patients 12 and older with Severe Eosinophilic Asthma)
CA Approval Date: 2018. 02.26.
EU Approval Date: 2018. 01.10.
USA Approval Date: 2017. 11.15.
(*) Company; TradeMark & Web-Site Available on Request.
UpDate: 2018. 01.11.




Asthma. TREAT.: MepolizuMAb SubCutaneous Inj.
IL-5 AntAgonist.
USA Approval Date: 2015. 11.04.>
> >12 Years
USA Approval Date: 2019. 09.12.>
> 6-11 Years
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 09.14.




COPD. TREAT.: Glycopyrrolate) Inhalation Solution (25 mcg twice daily).
Including Chronic Bronchitis and/or Emphysema.
First Nebulized LAMA.
USA Approval Date: 2017. 12.05.
USA Launch Date: 2018. 04.03.
(*) Company & TradeMark Available on
Request.
UpDate: 2018. 04.04.




Cystic Fibrosis (CF). DIAG.: Advanced
Sweat Collection System.
USA Launch Date: 2018. 08.16.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 08.17.




Cystic Fibrosis (CF). TREAT.: Ivacaftor
Oral Granule.
EU Approval Date: 2018. 11.29. (1-2 Y.)
USA Approval Date: 2015. 03.17. (>2 Y.)
USA Approval Date: 2018. 08.15. (1-2 Y.)
(*) Company; Patents; TradeMark &
Web-Site Available on Request.
UpDate: 2018. 11.30.




Cystic Fibrosis. TREAT.: Ivacaftor+Lumacaftor Tablets.
(in patients age 6 years and older who have two copies of the F508del mutation (F508del/F508del) in their CFTR gene.)
CA Approval Date : 2018. 12.13. 2-5Y
EU Approval Date : 2017. 01.10.
USA Approval Date: 2016. 09.28. >6Y
USA Approval Date: 2018. 08.07. 2-5Y
(*) Company : Vertex Pharma.
TradeMark: Orkambi.
Web-Site : www.orkambi.com
UpDate: 2018. 12.14.




Cystic Fibrosis. TREAT.: Ivacaftor+Tezacaftor Tablets.
(in patients age 6 years and older who have two copies of th e F508del mutation (F508del/F508del) in their CFTR gene.)
EU Approval Date : 2018. 11.01.
USA Approval Date: 2018. 02.12.
(*) Company : Vertex Pharma.
TradeMark (EU) : SYMKEVI
TradeMark (USA): SYMDEKO
Web-Site (USA): www.symdeko.com
UpDate: 2018. 11.03.




Diagnostics. Lung 4D X-Ray Imaging Tech-
nology.
USA Clearance Date: 2020. 05.25.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 03.04.




Inhaler. Use.
Properly using an inhaler is critical to dose consistency.
Asthma; COPD
(*) Company: Uneva Health Inc. unevahealth.com/
UpDate: 2018. 02.28.




Pleural Effusions. Treat.: Products ..
(*) Company; Patent; Products Name &
Web-Site Available on Request.
UpDate: 2020. 09.18.




Pleural Effusions. Treat.: Pump Drainage
System.
USA Launch Date: 2020. 08.28.
(*) Company; Patent APP.; TradeMark &
Web-Site Available on Request.
UpDate: 2020. 09.18.




Pulmonary Alveolar Proteinosis (PAP).
Diag.: Confocal Laser EndoMicroscopy
(CLE) (Device)+Fluorescein (Drug)
Combination.
USA Approval Date: 2020. 01.27.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 03.08.


>PNEUMOLOGY.'s products
This section has no products